Long-term survival of patients with recurrent endometrial stromal sarcoma: a multicenter, observational study.
10.3802/jgo.2015.26.3.214
- Author:
Hiroyuki YAMAZAKI
1
;
Yukiharu TODO
;
Kenrokuro MITSUBE
;
Hitoshi HAREYAMA
;
Chisa SHIMADA
;
Hidenori KATO
;
Katsushige YAMASHIRO
Author Information
1. Division of Gynecologic Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. yukiharu@sap-cc.go.jp
- Publication Type:Original Article ; Multicenter Study ; Observational Study
- Keywords:
Aromatase Inhibitors;
Gonadotropin-Releasing Hormone;
Retrospective Studies;
Sarcoma, Endometrial Stromal;
Survival Rate
- MeSH:
Adult;
Aged;
Antineoplastic Agents, Hormonal/therapeutic use;
Chemotherapy, Adjuvant/mortality;
Disease-Free Survival;
Endometrial Neoplasms/drug therapy/*mortality/surgery;
Female;
Humans;
Middle Aged;
Neoplasm Recurrence, Local/*mortality;
Retrospective Studies;
Sarcoma, Endometrial Stromal/drug therapy/*mortality/surgery;
Treatment Outcome
- From:Journal of Gynecologic Oncology
2015;26(3):214-221
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of this study was to evaluate the clinical behavior and management outcome of recurrent endometrial stromal sarcoma (ESS). METHODS: A retrospective review of charts of 10 patients with recurrent ESS was performed and relapse-free interval, relapse site, treatment, response to treatment, duration of follow-up and clinical outcome extracted. Survival outcome measures used were post-relapse survival which was defined as the time from first evidence of relapse to death from any cause. Living patients were censored at the date of last follow-up. RESULTS: The median age and median relapse-free interval at the time of initial relapse were 51.5 years and 66.5 months, respectively. The number of relapses ranged from one to five. Sixteen surgical procedures for recurrent disease included nine (56.0%) complete resections. There was no statistically significant difference between initial recurrent tumors and second/subsequent recurrent tumors in the rate of complete surgery (44.4% vs. 71.4%, respectively, p=0.36). Of the eleven evaluable occasions when hormonal therapy was used for recurrent disease, disease control was achieved in eight (72.7%). There was no difference between initial recurrent tumors and second/subsequent recurrent tumors in disease control rate by hormonal therapy (85.7% vs. 50.0%, respectively, p=0.49). The 10-year post-relapse survival rate was 90.0% and the overall median post-relapse survival 119 months (range, 7 to 216 months). CONCLUSION: Post-relapse survival of patients with ESS can be expected to be >10 years when treated by repeated surgical resection and hormonal therapy or both.
